| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO and President | Director
2 companies
Stengone Carmine N. serves as a CEO and President at CTNM and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 1 buy and 7 sells. Those positions are worth an estimated $288K at current prices.
The biggest single holding is CTNM (~$283K) as CEO and President. The recent filings there lean toward selling, a net 25,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 2,500 | $16.46 | $41,141.50 | -12.7% | - | - | |
| Aug 3, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 2,500 | $16.01 | $40,029.00 | -12.7% | - | - | |
| Jul 8, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 2,500 | $16.00 | $40,000.00 | -12.7% | -19.2% | - | |
| Jun 30, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 10,000 | $16.01 | $160,080.00 | -36.7% | -22.3% | - | |
| Feb 25, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 7,100 | $16.02 | $113,727.65 | -32.2% | -13.2% | - | |
| Feb 11, 2026 | CTNM Contineum Therapeutics, Inc. | CEO and President | Sale+OE10b5-1 | 400 | $16.00 | $6,400.00 | -2.6% | -10.5% | - | |
| Sep 11, 2024 | KPRX Kiora Pharmaceuticals Inc | Director | Buy | 1,250 | $3.68 | $4,600.00 | New | +1.7% | -24.6% |